EXTON, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc. today announced that an open label clinical study of OT-551 in patients with bilateral Geographic Atrophy (GA) has reached its enrollment target of 10 patients. OT-551 is Othera’s lead small molecule topical eye drop currently in development for treating the dry and wet forms of age-related macular degeneration (AMD) and cataracts. OT-551 could represent the first effective treatment for GA, a chronic, degenerative disease which currently affects about 1 million elderly Americans.
